In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 29, No. 18 ( 2023-05), p. 1459-1465
Abstract:
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers
(ARB) are mainly known as anti-hypertensive drugs. Recent evidence suggests their anti-tumor potential against renal cancer. More than one-fourth of patients present with metastasis on their first visit. Objective: The purpose of the current study was to examine the potential clinical impact of ACEI/ARB on metastatic
renal cell carcinoma (mRCC). Methods: We searched through several online databases, including Pubmed, Scopus, Web of Science, and Embase,
to find clinical studies that have investigated the association between treatment with ACEI/ARB and the survival of patients with mRCC. The hazard ratio (HR) and 95% confidence interval (95% CI) were utilized to
assess the strength of the association. Results: A total of 6 studies with a total number of 2,364 patients were found eligible for the final analysis. The HR for the relationship between ACEI/ARB use and overall survival (OS) showed patients undergoing treatment
with ACEI/ARB to have higher OS than non-users (HR: 0.664, 95% CI 0.577-0.764, p = 0.000). Furthermore, the HR for the relationship between ACEI/ARB use and progression-free survival (PFS) showed patients
undergoing treatment with ACEI/ARB to have higher PFS than non-users (HR: 0.734, 95% CI 0.695-0.794, p = 0.000). Conclusion: The results of this review offer ACEI/ARB as a potential therapeutic option associated with improved
survival outcomes in patients receiving anti-vascular endothelial growth factor therapy.
Type of Medium:
Online Resource
ISSN:
1381-6128
DOI:
10.2174/1381612829666230524152108
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023
SSG:
15,3
Permalink